Johnson and Johnson: cross-border access for the specialty portfolio

Quick orientation

Johnson and Johnson is a US-headquartered diversified healthcare company based in New Brunswick, New Jersey. Its pharmaceutical division, formerly branded Janssen and rebranded in 2024 as Johnson and Johnson Innovative Medicine, holds the largest concentration of specialty prescription products in the group. Therapeutic focus areas are immunology (Stelara, Tremfya, Remicade), oncology and hematology (Darzalex, Tecvayli, Talvey, Carvykti, Erleada, Akeega in advanced prostate), neuroscience (Spravato; Invega long-acting injectables), pulmonary hypertension (Opsumit, Uptravi, Tracleer through the Actelion acquisition), and infectious disease.

For cross-border named-patient program activity, the J and J Innovative Medicine oncology franchise (multiple myeloma CD38, BCMA and GPRC5D agents and recently expanded prostate cancer combinations) generates the highest volume of Reserve Meds inquiries, followed by immunology biologic indication-expansion cases.

Portfolio in cross-border NPP scope

Stelara (ustekinumab)

IL-12 and IL-23 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. US WAC for the standard subcutaneous maintenance schedule has historically run in the $80,000-per-year range. Cross-border requests are predominantly for the IV induction kit used in IBD (often unavailable locally), the pediatric weight-banded dose for juvenile psoriasis, and originator product where the patient is intolerant to a locally available biosimilar.

Tremfya (guselkumab)

IL-23 inhibitor approved for plaque psoriasis, psoriatic arthritis, and ulcerative colitis. Reserve Meds coordinates Tremfya primarily for IBD patients where the new UC and Crohn's indications are not yet locally registered, and for patients in the Gulf with severe psoriasis who have failed IL-17 and TNF biologics.

Darzalex and Darzalex Faspro (daratumumab)

CD38-directed monoclonal antibody approved across newly diagnosed and relapsed and refractory multiple myeloma. US WAC for the standard maintenance schedule runs above $200,000 per year. Cross-border requests overwhelmingly favor the Faspro subcutaneous formulation where the local market still stocks only the IV form, and for the newly diagnosed transplant-ineligible quadruplet regimens that have not yet been locally added to label.

Tecvayli (teclistamab)

BCMA and CD3-directed bispecific T-cell engager approved for relapsed and refractory multiple myeloma after at least four prior lines including a PI, IMiD, and anti-CD38 antibody. International requests come from triple-class refractory myeloma patients in MENA and India where the locally available BCMA pathway is either CAR-T (limited capacity) or no approved BCMA option at all.

Talvey (talquetamab)

GPRC5D and CD3-directed bispecific T-cell engager approved for relapsed and refractory multiple myeloma in patients who have received at least four prior lines. Cross-border requests cluster around triple-class refractory myeloma patients who have already failed teclistamab and need a non-BCMA mechanism.

Carvykti (ciltacabtagene autoleucel)

BCMA-directed autologous CAR-T cell therapy for relapsed and refractory multiple myeloma. Reserve Meds does not coordinate Carvykti cross-border because the autologous-cell-collection logistics anchor delivery to a US apheresis and manufacturing site; we redirect those inquiries to medical-travel pathway documentation.

Erleada (apalutamide) and Akeega (niraparib and abiraterone)

Erleada is an androgen receptor inhibitor approved for non-metastatic CRPC and metastatic castration-sensitive prostate cancer. Akeega is the fixed-dose combination of niraparib plus abiraterone for BRCA-mutated metastatic CRPC. Both surface predominantly through Reserve Meds for prostate cancer patients in India and the Gulf where the combination indication or the nmCRPC indication has not yet been added to the local label.

Spravato (esketamine)

Nasal spray approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Spravato is delivered in a REMS-restricted in-clinic setting in the US. Reserve Meds does not coordinate Spravato cross-border because the REMS administration model anchors product to a US-certified clinic; we redirect those inquiries to medical-travel routing.

Opsumit (macitentan) and Uptravi (selexipag)

Endothelin receptor antagonist (Opsumit) and prostacyclin receptor agonist (Uptravi) for pulmonary arterial hypertension. Reserve Meds coordinates these primarily for PAH patients in MENA where the combination triple-therapy approach is locally unsupported by reimbursement, or where the Uptravi titration pack is not stocked.

Why patients route J and J products through cross-border NPP

Three patterns dominate. First, the multiple myeloma franchise (Darzalex, Tecvayli, Talvey, Carvykti) expands FDA-labeled indications and combinations faster than MENA and India regulators add the corresponding local label updates. Patients in triple-class refractory myeloma who are eligible for Tecvayli or Talvey often have no locally registered comparable option.

Second, the immunology franchise (Stelara, Tremfya, Remicade) has indication-expansion gaps in IBD across the MENA payer landscape. Stelara IV induction kits and pediatric weight-banded dosing are the most commonly unavailable presentations.

Third, the Johnson and Johnson Patient Assistance Foundation and product-specific support programs are restricted to US residents. International patients route as cash-pay through the named-patient pathway.

Manufacturer engagement posture

Reserve Meds coordinates Johnson and Johnson Innovative Medicine US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized Johnson and Johnson distributor; we are an independent named-patient program coordinator. Patient assistance program coverage does not extend to cross-border patients. All Reserve Meds orders are cash-pay at firm-quote pricing.

For J and J Innovative Medicine market access, medical affairs, and international new product planning teams: Reserve Meds carries structured demand visibility across the myeloma bispecifics, prostate cancer combinations, and IBD biologic franchises. If your group is sizing pre-registration demand or evaluating named-patient program activity in MENA and India ahead of formal launch, we are open to a structured conversation under NDA.

Common cross-border destinations for the J and J portfolio

The myeloma bispecific franchise (Tecvayli, Talvey, Darzalex Faspro) concentrates in Saudi Arabia, UAE, India, and Egypt where hematology centers of excellence carry the volume. The IBD biologic franchise (Stelara, Tremfya) skews to the Gulf and Egypt. The prostate cancer franchise (Erleada, Akeega) is heaviest in India and the Gulf.

What Reserve Meds provides

For every J and J Innovative Medicine product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator who carries the case from inquiry through delivery confirmation. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before the order is released for dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a J and J product and want a firm quote can start a request below.

Start a request for a J and J product

Next step for Johnson and Johnson teams

If you are on the J and J Innovative Medicine access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.